ArticleWorld journal of urology2026
Years of life lost and mortality rates from metastatic prostate cancer in contemporary African Americans vs. Caucasians.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Years of Life Lost From Metastatic Prostate Cancer According to Treatment Era and Race/Ethnicity.The Prostate · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIt is unknown whether the historical survival disadvantage of African American metastatic prostate cancer (mPCa) patients persists in abiraterone and androgen receptor pathway inhibitors (ARPIs) eras.
methodsIn Surveillance, Epidemiology, and End Results (SEER) database (2017–2021), African American and Caucasian mPCa patients aged 40–80 years treated across abiraterone (2017–2018) and ARPI (2019–2021) eras were identified. Age- and sex-matched controls were generated (Social Security Administration life tables and Monte Carlo simulation). Years of life lost (YLL) were quantified for mPCa patients and controls. Subsequently, propensity score matching (PSM) and multivariable competing-risks regression (CRR) models were used.
resultsIn abiraterone era, YLL were 8.1 in African Americans vs. 5.4 in Caucasians (Δ: 2.7). In ARPI era, YLL were 4.6 in African Americans vs. 2.6 in Caucasians (Δ: 2.0). The 24-months cancer-specific mortality (CSM) was 30.3% in African Americans vs. 25.4% in Caucasians (multivariable hazard ratio [mHR]: 1.21, p < 0.001) in abiraterone era and 23.3% in African Americans vs. 25.0% in Caucasians (mHR: 1.01, p = 0.8) in ARPI era. The 24-months other-cause mortality (OCM) was 6.6% in African Americans vs. 5.1% in Caucasians (mHR: 1.27, p = 0.039) in abiraterone era and 8.9% in African Americans vs. 5.3% in Caucasians (mHR: 1.87, p < 0.001) in ARPI era.
conclusionThe current data indicate more favorable YLL values exhibited by African Americans in ARPI era relative to abiraterone era, that stand from lower contributions of CSM, but stable contributions of OCM.
Indexed as
Identifiers
41729247What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.